Drilldown: Medicines
Medicines > classes 
:
Antidepressant or
Benzodiazepine or
[[:Category:Overactive_bladder_medications|Overactive bladder medication]]
:
Antidepressant or
Benzodiazepine or
[[:Category:Overactive_bladder_medications|Overactive bladder medication]] Use the filters below to narrow your results.
generic:
brand:
None (10) ·
Anafranil (1) ·
Aurorix (1) ·
Cymbalta, Drizalma Sprinkle, Irenka, Yentreve (1) ·
Dalmane (1) ·
Ditropan, Ditropan XL, Oxytrol (transdermal), Gelnique (gel) (1) ·
Doral (1) ·
Edronax (1) ·
Fetzima (1) ·
Halcion (1) ·
Lexotan (1) ·
Librium (1) ·
Ludiomil (1) ·
Marplan (1) ·
Mogadon (1) ·
Myrbetriq (1) ·
Nardil (1) ·
Norpramin (1) ·
Onfi (1) ·
Parnate (1) ·
ProSom (1) ·
Restoril (1) ·
Rohypnol (1) ·
Savella (1) ·
Serax (1) ·
Serzone (1) ·
Stablon (1) ·
Surmontil (1) ·
Tofranil (1) ·
Tranxene (1) ·
Valdoxan (1) ·
Versed (1) ·
Vesicare (1) ·
Vivactil (1) ·
Xanax (1) ·
Zoloft (1)
classes: (Click arrow to add another value)
mechanism:
None (2) ·
Extremely potent GABAA positive allosteric modulator (1) ·
GABA-A positive allosteric modulator'"`UNIQ--ref-00000067-QINU`"' '"`UNIQ--vote-00000068-QINU`"' (1) ·
GABAA positive allosteric modulator (18) ·
GABAA positive allosteric modulator; low sedation (1) ·
GABAA positive allosteric modulator; prodrug of desmethyldiazepam (1) ·
GABAA positive allosteric modulator; very long half-life (1) ·
Irreversible non-selective MAO inhibitor (3) ·
Melatonin receptor agonist; 5-HT2C antagonist (1) ·
Mu-opioid agonist; modulates glutamate AMPA receptors (1) ·
Potent serotonin reuptake inhibitor; also NRI (1) ·
Reversible inhibitor of MAO-A (1) ·
Selective norepinephrine reuptake inhibitor (3) ·
Serotonin and norepinephrine reuptake inhibitor (3) ·
Serotonin reuptake inhibitor and 5-HT2A antagonist (1) ·
Serotonin–norepinephrine reuptake inhibition (balanced) (1) ·
Serotonin–norepinephrine reuptake inhibitor (2) ·
TrkB/BDNF'"`UNIQ--ref-00000084-QINU`"' '"`UNIQ--vote-00000085-QINU`"' (1) ·
Weak SRI; primarily H1/D2/alpha antagonist (1) ·
'"`UNIQ--vote-00000DFA-QINU`"' CYP3A4 substrate; QT-interval prolongation has been reported at higher doses. Like other antimuscarinics, contributes to cumulative anticholinergic burden in older adults'"`UNIQ--ref-00000DFB-QINU`"'. (1)
uses:
None (40) ·
Depression, anxiety, neuropathic pain, fibromyalgia, chronic musculoskeletal pain (1) ·
'"`UNIQ--vote-00000069-QINU`"', '"`UNIQ--vote-0000006A-QINU`"', '"`UNIQ--vote-0000006B-QINU`"' (1) ·
'"`UNIQ--vote-000006DE-QINU`"', '"`UNIQ--vote-000006DF-QINU`"', '"`UNIQ--vote-000006E0-QINU`"' (1) ·
'"`UNIQ--vote-00000C4C-QINU`"', '"`UNIQ--vote-00000C4D-QINU`"' (1) ·
'"`UNIQ--vote-00000DFC-QINU`"', '"`UNIQ--vote-00000DFD-QINU`"' (1)
starting dose:
preparations:
None (40) ·
0.25 mg, 0.5 mg, 1 mg, 2 mg tablets (immediate-release and orally disintegrating); 0.5 mg, 1 mg, 2 mg, 3 mg extended-release tablets; 1 mg/mL oral concentrate (1) ·
25 mg, 50 mg, 100 mg tablets; oral concentrate 20 mg/mL (1) ·
25, 50 mg ER tablets; 8 mg/mL granules for oral suspension (Myrbetriq Granules, pediatric) (1) ·
5 mg IR tablets; 5, 10, 15 mg ER tablets; 5 mg/5 mL syrup; 3.9 mg/24 h transdermal patch (Oxytrol); 10% topical gel (1) ·
5, 10 mg tablets (1)
fda max:
routes:
onset:
None (39) ·
30-60 min (immediate-release); 1-2 h (extended-release) (1) ·
30-60 minutes (PO) (1) ·
Anxiolysis classically 3-4 weeks, continuing improvement to 8-12 weeks (1) ·
Mood: 2–4 weeks. Pain: often within 1–2 weeks. (1) ·
Symptom improvement within 1-2 weeks (1) ·
Symptom improvement within weeks (1)
duration:
halflife:
None (39) ·
11-13 h (immediate-release); 11-16 h (extended-release) (1) ·
2-3 hours (parent and active N-desethyl metabolite)'"`UNIQ--ref-000006E1-QINU`"' (1) ·
~12 hours (1) ·
~26 h (sertraline; range 13-45 h, longer in females); ~62-104 h (N-desmethylsertraline, weakly active) (1) ·
~45-68 hours'"`UNIQ--ref-00000DFE-QINU`"' (1) ·
~50 hours'"`UNIQ--ref-00000C4E-QINU`"' (1)
bioavailability:
None (39) ·
25 mg: ~29%; 50 mg: ~35%; food reduces absorption'"`UNIQ--ref-00000C4F-QINU`"' (1) ·
80-90% oral (1) ·
Absolute bioavailability not precisely characterized; food modestly increases exposure (1) ·
~50% (highly variable) (1) ·
~6% IR oral (substantial first-pass to active N-desethyl metabolite, which contributes most of the antimuscarinic adverse effects); transdermal bypasses first-pass and is better tolerated'"`UNIQ--ref-000006E2-QINU`"' (1) ·
~90% (oral)'"`UNIQ--ref-00000DFF-QINU`"' (1)
pregnancy:
Showing below up to 45 results in range #1 to #45.